MX371279B - Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. - Google Patents

Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.

Info

Publication number
MX371279B
MX371279B MX2015005174A MX2015005174A MX371279B MX 371279 B MX371279 B MX 371279B MX 2015005174 A MX2015005174 A MX 2015005174A MX 2015005174 A MX2015005174 A MX 2015005174A MX 371279 B MX371279 B MX 371279B
Authority
MX
Mexico
Prior art keywords
symptoms associated
behavioral
prophylactic
salt
therapeutic agent
Prior art date
Application number
MX2015005174A
Other languages
English (en)
Other versions
MX2015005174A (es
Inventor
Maeda Kenji
Nakamura Mai
Sato Shinji
Ishikawa Dai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2015005174A publication Critical patent/MX2015005174A/es
Publication of MX371279B publication Critical patent/MX371279B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a un agente profiláctico y/o terapéutico para los síntomas conductuales y psicológicos asociados con enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental, que contiene 7-[4-(4--benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2 -ona o una de sus sales como un ingrediente activo.
MX2015005174A 2012-10-25 2013-10-24 Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. MX371279B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718305P 2012-10-25 2012-10-25
US201361782467P 2013-03-14 2013-03-14
PCT/JP2013/079480 WO2014065437A1 (en) 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

Publications (2)

Publication Number Publication Date
MX2015005174A MX2015005174A (es) 2015-09-04
MX371279B true MX371279B (es) 2020-01-24

Family

ID=49585556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005174A MX371279B (es) 2012-10-25 2013-10-24 Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.

Country Status (22)

Country Link
US (4) US20150272946A1 (es)
EP (2) EP3848033A1 (es)
JP (5) JP6329140B2 (es)
KR (1) KR102245016B1 (es)
CN (4) CN112402421A (es)
AR (1) AR093247A1 (es)
AU (1) AU2013335613B2 (es)
BR (1) BR112015008759A2 (es)
CA (1) CA2889196C (es)
EA (1) EA201590808A1 (es)
HK (1) HK1212609A1 (es)
IL (1) IL238402B (es)
JO (2) JOP20210047A1 (es)
MX (1) MX371279B (es)
MY (1) MY180185A (es)
NZ (1) NZ708321A (es)
PH (1) PH12015500925A1 (es)
SG (2) SG11201503152TA (es)
TW (1) TWI643620B (es)
UA (1) UA116549C2 (es)
WO (1) WO2014065437A1 (es)
ZA (1) ZA201503640B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533369C (en) 2003-07-22 2009-07-14 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN104739829B (zh) 2008-10-28 2018-11-06 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
MX2016013889A (es) * 2014-04-22 2017-03-09 Otsuka Pharma Co Ltd Medicamento.
WO2016115144A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
JP2018502158A (ja) * 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ，インコーポレイティド パーキンソン病と関連する精神病の治療方法
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
JP2018520187A (ja) * 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3088356A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
MX2020005518A (es) 2017-12-05 2020-11-06 Sunovion Pharmaceuticals Inc Mezclas no racemicas y usos de las mismas.
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
JP2021529737A (ja) 2018-06-20 2021-11-04 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンを含有する経皮治療システム
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JPWO2021029020A1 (es) * 2019-08-13 2021-02-18
WO2021261571A1 (ja) * 2020-06-24 2021-12-30 国立大学法人北海道大学 血液脳脊髄関門保護剤
CN112137994B (zh) * 2020-09-15 2022-10-14 中山大学 小分子化合物在制备抗丝状病毒药物中的应用
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EP2822136B1 (en) * 2013-07-03 2018-08-29 Siemens Aktiengesellschaft Method and arrangement for transferring electrical power for subsea applications

Also Published As

Publication number Publication date
EP2911670A1 (en) 2015-09-02
KR102245016B1 (ko) 2021-04-26
CA2889196C (en) 2021-02-16
MY180185A (en) 2020-11-24
JP2020045345A (ja) 2020-03-26
US20170258787A1 (en) 2017-09-14
AU2013335613A1 (en) 2015-06-04
KR20150074156A (ko) 2015-07-01
SG10201702828TA (en) 2017-05-30
JP2023123441A (ja) 2023-09-05
EP3848033A1 (en) 2021-07-14
HK1212609A1 (zh) 2016-06-17
JOP20210047A1 (ar) 2017-06-16
JP2021181448A (ja) 2021-11-25
US20150272946A1 (en) 2015-10-01
NZ708321A (en) 2019-03-29
CN112402421A (zh) 2021-02-26
TW201427665A (zh) 2014-07-16
CN114712360A (zh) 2022-07-08
PH12015500925B1 (en) 2015-06-29
EA201590808A1 (ru) 2015-08-31
AR093247A1 (es) 2015-05-27
BR112015008759A2 (pt) 2017-07-04
JP2015535211A (ja) 2015-12-10
US20220370442A1 (en) 2022-11-24
WO2014065437A1 (en) 2014-05-01
SG11201503152TA (en) 2015-05-28
CA2889196A1 (en) 2014-05-01
MX2015005174A (es) 2015-09-04
CN104755082A (zh) 2015-07-01
JP2018138555A (ja) 2018-09-06
IL238402B (en) 2018-11-29
ZA201503640B (en) 2016-08-31
IL238402A0 (en) 2015-06-30
JOP20130313B1 (ar) 2021-08-17
TWI643620B (zh) 2018-12-11
PH12015500925A1 (en) 2015-06-29
UA116549C2 (uk) 2018-04-10
AU2013335613B2 (en) 2018-07-12
JP6329140B2 (ja) 2018-05-23
CN108578408A (zh) 2018-09-28
US20190314367A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
MX371279B (es) Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.
TN2015000278A1 (en) Autotaxin inhibitors
GEP20166554B (en) Nitrogenated heterocyclic compound
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
PH12014501671B1 (en) Amidine substituted beta-lactam compounds, their preparation and use as antibacterial agents
MX361723B (es) Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo.
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MX2013008500A (es) Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
AR093527A1 (es) 6-((S)-1-1-[5-(2-HIDROXI-ETOXI)-PIRIDIN-2-IL]1H-PIRAZOL-3-IL-ETIL)-3H-1,3-BENZOTIAZOL-2-ONA COMO UN ANTAGONISTA DEL RECEPTOR AMPA DEPENDIENTE DE TARP-g 8
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
WO2014056779A8 (de) Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung
WO2012169785A3 (en) Symmetrically structured quinazoline derivatives
GB201206984D0 (en) New therapeutic use
IN2014KN02584A (es)
EA202193278A1 (ru) Средство для профилактики и/или лечения поведенческих и психотических симптомов, связанных с нейродегенеративным заболеванием, или симптомов импульсивности, связанных с психическим заболеванием, содержащее брекспипразол или его соль
IT1403778B1 (it) Veicolo trainato, particolarmente atto all'impiego agricolo o forestale
IN2014DE00700A (es)
GEP201606554B (en) Nitrogenated heterocyclic compound
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
MD4291B1 (ro) Preparat medicamentos pentru tratamentul otitelor

Legal Events

Date Code Title Description
FG Grant or registration